The therapy and dosing regimen delivered in our clinics for people with alcohol problems was developed and tested through Awakn Life Sciences’ clinical trials for KARE (Ketamine in the Reduction of Alcoholic Relapse). These trials showed ketamine-assisted therapy delivered 86% abstinence at 6 months post-treatment, significantly more than the approximate 25% abstinence in the standard treatment. Trial participants also experienced significant improvement in liver function and a substantial decrease in depression. Anecdotally, many participants also reported sudden profound changes and ease of giving up after struggling for years. The results were published in the American Journal of Psychiatry in January 2022. Because psychedelic-assisted therapy is effective at addressing underlying traumas that are linked to harmful repetitive thinking patterns, it presents the possibility of addressing a wide range of mental health issues rooted in trauma. Click here for details of clinical trial outcomes.